Zobrazeno 1 - 10
of 5 799
pro vyhledávání: ''
Autor:
Hélène Labussière-Wallet, Stephanie Nguyen-Quoc, Amandine Luc, Thomas Remen, Jacques-Olivier Bay, Edouard Forcade, Rémi Dulery, Marie-Thérèse Rubio, Célestine Simand, Micha Srour, Maud d'Aveni, Ambroise Marçais, Sabine Furst, Arnaud Campidelli, Patrice Ceballos, Etienne Daguindau, Marie Robin, Pascal Turlure
Publikováno v:
Clinical Lymphoma, Myeloma & Leukemia
Clinical Lymphoma, Myeloma & Leukemia, Elsevier, In press, ⟨10.1016/j.clml.2021.07.027⟩
Clinical Lymphoma, Myeloma & Leukemia, Elsevier, In press, ⟨10.1016/j.clml.2021.07.027⟩
International audience; BackgroundAllogeneic hematopoietic stem-cell transplantation (allo-HSCT) remains the best curative option for high-risk myelodysplastic syndrome . We retrospectively compared patient outcomes after allo-HSCT according to the i
Autor:
Fred R. Hirsch, Sarah M. Paul, Keunchil Park, C. Matheny, Achim Rittmeyer, Jing Yi, Wei Zou, Marcus Ballinger, Mark McCleland, Fabrice Barlesi, Keith M. Kerr, Shirish M. Gadgeel, Hartmut Koeppen, David R. Gandara, David S. Shames, Namrata Bhatia
Publikováno v:
Clinical Lung Cancer. 23:21-33
BACKGROUND This phase III OAK trial (NCT02008227) subgroup analysis (data cutoff, January 9, 2019) evaluated the predictive value of 2 PD-L1 IHC tests (VENTANA SP142 and Dako 22C3) for benefit from atezolizumab versus docetaxel by programmed death li
Autor:
Yunfei Wang, Yin Wan, Nicholas J. Vogelzang, Yiqiong Xie, Nicholas J. Robert, Alisha M. Monnette, Nizar M. Tannir
Publikováno v:
Clinical Genitourinary Cancer. 19:531-539
Introduction Few studies have evaluated real-world effectiveness of lenvatinib (Len)/everolimus (Eve) for advanced/metastatic renal cell carcinoma (a/mRCC). This study evaluated patient profiles and clinical outcomes of second- and subsequent-line (
Autor:
Huabin Hu, Weiwei Li, Xiaoyu Xie, Jianxia Li, Miaomiao Ding, Jianwei Zhang, Zehua Wu, Jiayu Ling, Yue Cai, Yanhong Deng
Publikováno v:
Clinical Colorectal Cancer. 20:e240-e248
To evaluate the predictive implications and prognosis of mucinous adenocarcinoma (MAC) in locally advanced rectal cancer (LARC) with intensified neoadjuvant treatment.Individual patient data of LARC patients from 3 prospective clinical trials was ana
Autor:
Abhinav Zawar, Suresh Kumar Bondili, Manju Sengar, Lingaraj Nayak, Navin Khattry, Jayashree Thorat, Pradeep Ventrapati, Hashmukh Jain, Anant Gokarn, Sachin Punatar, Bhausaheb Bagal, Avinash Bonda
Publikováno v:
JCO Global Oncology
PURPOSE The prognosis of relapsed and refractory multiple myeloma (RRMM) that is refractory to bortezomib and lenalidomide is very poor wherein the median survival is between 3 and 9 months. We did this retrospective analysis to study the pattern of
Publikováno v:
Clinical Colorectal Cancer. 20:e215-e225
Background Suboptimal completion of chemotherapy, which may involve reduced patient adherence, remains a serious issue and leads to reduced treatment efficacy. This study assessed the completion rates, risk factors for noncompletion, and cost impact
Autor:
Tatiana Gamez, Carlos Vargas, Christian Rolfo, Pilar Archila, Luis Corrales, Oscar Arrieta, Claudio Martin, Jorge Otero, C. Sotelo, Hernán Carranza, Juan Esteban Garcia-Robledo, D. Mayorga, Luisa Ricaurte, Camila Ordóñez-Reyes, Lucia Zatarain Barron, L. Rojas, Rafael Rosell, Luis Mas, Alejandro Ruiz-Patiño, Maritza Bermudez, July Rodriguez, J. Ávila, Andrés F. Cardona, Gonzalo Recondo, Feliciano Barrón
Publikováno v:
Repositorio U. El Bosque
Universidad El Bosque
instacron:Universidad El Bosque
Universidad El Bosque
instacron:Universidad El Bosque
La activación de BIM es esencial para la apoptosis desencadenada por el inhibidor de la tirosina quinasa (TKI) del receptor del factor de crecimiento epidérmico (EGFR) en el cáncer de pulmón de células no pequeñas (CPCNP) con mutación de EGFR.
Autor:
Igor Tsaur, Jarmo C B Hunting, Alexander Kretschmer, Derya Tilki, Giorgio Gandaglia, Jasmin Bektic, Hendrik Borgmann, Robert Dotzauer, Roderick C.N. van den Bergh, Guillaume Ploussard, Isabel Heidegger, Silvia Foti
Publikováno v:
European Urology Focus. 7:1308-1315
Background: Besides second-generation hormone therapy (sHT), upfront docetaxel along with androgen deprivation therapy is the current standard of care for metastasized hormone-sensitive prostate cancer (mHSPC). Evidence on second-line therapy upon pr
Autor:
Min Xuan, Ting Gao, Peiyu Huang, Quanquan Gu, Minming Zhang, Linbo Wang, Xueqin Bai, Tao Guo, Jianfeng Feng, Cheng Zhou, Xiaojun Guan, Jingjing Wu, Luyan Gu, Wei Cheng, Baorong Zhang, Xiaojun Xu
Publikováno v:
Journal of Parkinson's Disease
Background: The widely divergent responsiveness of Parkinson’s disease (PD) patients to levodopa is an important clinical issue because of its relationship with quality of life and disease prognosis. Preliminary animal experiments have suggested th
Autor:
Nicola Longo, Daniela Terracciano, Francesco Del Giudice, Giuseppe Lucarelli, Angelo Porreca, Pasquale Ditonno, Angelo Luciano, Carlo Buonerba, Alessandro Antonelli, Vincenzo Caputo, Rocco Damiano, Pasquale Dolce, Michele Marchioni, Fabio Crocerossa, Paolo Gontero, Stefania Zamboni, Matteo Manfredi, Antonio Verde, Michele Battaglia, Dario Ribera, Francesco Porpiglia, Gennaro Musi, Francesco Cantiello, Andrea Minervini, Felice Crocetto, Ottavio De Cobelli, Giuseppe Celentano, Vincenzo Cosimato, Mihai Dorin Vartolomei, Nicolae Crisan, Andrea Mari, Giorgio Ivan Russo, Abdal Rahman Abu Farhan, Francesco Greco, Francesco Soria, Francesco Chiancone, Luca Scafuri, Paola Del Prete, Rodolfo Hurle, Pietro De Placido, Giuseppe Di Lorenzo, Sergio Facchini, Matteo Ferro, Riccardo Autorino, Sisto Perdonà, Gian Maria Busetto
Publikováno v:
Future Oncology. 17:3987-3994
The objective of the current research was to explore the potential prognostic value of readily available clinical and pathologic variables in bladder cancer. The novel association found between cholesterol levels and prognosis may provide the rationa